- Q2 2024 Rxsight Inc Earnings Call TranscriptAug 05, 2024$40.78 (-2.37%)Earnings
- Q1 2024 Rxsight Inc Earnings Call TranscriptMay 06, 2024$62.84 (+1.88%)Earnings
- Q4 2023 Rxsight Inc Earnings Call TranscriptFeb 28, 2024$56.39 (-2.64%)Earnings
- Rxsight Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Q3 2023 Rxsight Inc Earnings Call TranscriptNov 09, 2023$23.8 (-4.19%)Earnings
- Q2 2023 Rxsight Inc Earnings Call TranscriptAug 07, 2023$28.84 (-4.09%)Earnings
- Rxsight Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Q1 2023 Rxsight Inc Earnings Call TranscriptMay 09, 2023$19.25 (-0.82%)Earnings
- Rxsight Inc at Needham Healthcare Conference (Virtual) TranscriptApr 19, 2023
- Rxsight Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 13, 2023
- Q4 2022 Rxsight Inc Earnings Call TranscriptMar 06, 2023$15.69 (+12.96%)Earnings
- Rxsight Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Q3 2022 Rxsight Inc Earnings Call TranscriptNov 07, 2022$12.62 (+7.86%)Earnings
- Q2 2022 Rxsight Inc Earnings Call TranscriptAug 08, 2022$15.65 (-0.32%)Earnings
- Q1 2022 Rxsight Inc Earnings Call TranscriptMay 05, 2022$10.61 (-10.54%)Earnings
Rxsight Inc at JPMorgan Healthcare Conference Transcript
Hello, everyone. I'm Robbie Marcus, the med tech analyst at JPMorgan. Happy to introduce our next presentation, company is RxSight, I'm going to bring up CEO, Ron Kurtz, and then we'll do some Q&A. Ron?
Thank you very much, Robbie, and thank you for having us at the conference. These are forward-looking statements.
RxSight is focused on growing the premium cataract surgery market, which is the most profitable segment of the highest volume surgical procedure in ophthalmology. Our strategy is based on delivering both better medicine for patients and better business results for doctors and practices, an approach that our team has used previously to build high-margin premium pay businesses in ophthalmology over the past 20 years. As we will discuss, RxSight's first-in-class light adjustable lens or LAL, delivers unparalleled visual results for patients and drives growth of premium pay procedures that are critical to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)